CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis

Area of Science:

• Cardiovascular Medicine
• Immunology
• Pharmacology

Background:

• Atherosclerosis is now understood as a chronic inflammatory condition, not just lipid deposition.
• Evidence suggests that reducing vascular inflammation alone, without lowering lipoprotein levels, does not decrease adverse cardiovascular events.

Purpose of the Study:

• To evaluate the efficacy of canakinumab, an interleukin-1β (IL-1β) inhibitor, in reducing cardiovascular (CV) events.
• To assess the impact of anti-inflammatory therapy on CV outcomes in patients with established atherosclerosis.

Main Methods:

• The study involved patients with prior myocardial infarction who received canakinumab.
• Canakinumab, a monoclonal antibody, targets and neutralizes interleukin-1β.
• The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) was a randomized controlled trial.

Main Results:

• Canakinumab significantly reduced the rate of recurrent CV events in patients with a history of myocardial infarction.
• The treatment did not demonstrate any effect on cardiovascular or all-cause mortality.
• A notable increase in the incidence of fatal infections was observed in the canakinumab group.

Conclusions:

• Targeting vascular inflammation with canakinumab can reduce cardiovascular events in specific patient populations.
• The lack of mortality benefit and the increased risk of fatal infections raise concerns about the net clinical benefit.
• Further investigation is required to determine the role of anti-inflammatory therapies in clinical practice for cardiovascular disease management.